EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stem cells and derived growth factors in Alzheimer’s disease: mechanistic insights and translational perspectives

Rishika Dhapola, Sneha Kumari, Prajjwal Sharma, Mohit Paidlewar, Balachandar Vellingiri, Ssang-Goo Cho, Ahmed Abdal Dayem, Bikash Medhi, Dibbanti HariKrishnaReddy iD

Inflammopharmacology · 2026-11 · 34 (11) · 7009-7023

DOI: 10.1007/s10787-026-02418-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 03.10.2026. Verfasst von Rishika Dhapola und 8 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology, School of Health Sciences, Central University of Punjab, Ghudda, Bathi…. Hauptthemen laut MEDLINE: Alzheimer Disease, Intercellular Signaling Peptides and Proteins, Stem Cells. Die Arbeit nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a significant healthcare concern due to the complex interactions between amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, and progressive neuronal death. Stem-cell-based therapies have demonstrated potential to treat this complex condition through immunomodulation, trophic support, and neuroregeneration. Beyond direct cell replacement, stem-cell-derived growth factors have important therapeutic functions by providing strong neurotrophic and cytoprotective effects. These bioactive compounds improve neuronal survival, restore synaptic plasticity, and reduce inflammatory cascades that accelerate the course of AD. Important growth factors that support increased neural resilience, cholinergic preservation, synaptic strengthening, and mitochondrial stabilization include BDNF, NGF, and IGF-1. The current study synthesizes molecular knowledge and new clinical data to assess the translational potential of stem cells and their growth-factor secretome. According to preclinical research, neural stem cells (NSCs) increase synaptic density and maintain cholinergic integrity in APP/PS1 mice, while mesenchymal stem cells (MSCs) lower amyloid burden, inhibit microglial activation, and improve memory. The stem-cell secretome offers a significant therapeutic benefit. BDNF increases synaptic plasticity, NGF promotes cholinergic survival, and IGF-1 improves mitochondrial function and diminishes oxidative stress and tau-mediated toxicity. However, significant obstacles impede clinical advancement. Therapeutic stability is limited by the risks of tumorigenicity, poor long-term engraftment, immunological rejection, and irregular blood-brain barrier penetration. Major challenges persist, such as manufacturing inconsistency, scalability limitations, and difficulties attaining controlled growth-factor dosing. To advance stem-cell-based techniques for significant AD alterations, these hurdles must be overcome by biomaterial optimization, modified secretomes, and standardized production platforms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseIntercellular Signaling Peptides and ProteinsStem CellsHumansAnimalsNeuronal PlasticityStem Cell TransplantationNeural Stem Cells

Stichwörter der Autor:innen

Alzheimer’s diseaseGrowth factorsMechanismStem cellsTherapeutics

Substanzen

Intercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology, School of Health Sciences, Central University of Punjab, Ghudda, Bathinda, 151401, Punjab, India.
  • Neurobiology (Ageing and Pediatric) Laboratory, Department of Zoology, School of Basic Sciences, Central University of Punjab, Bathinda, 151401, Punjab, India.
  • Stem Cell and Regenerative Biotechnology Major, School of Advanced Biotechnology, College of Institute of Science and Technology, Molecular & Cellular Reprogramming Center, Institute of Advanced Regenerative Science, In…
  • Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
  • Advanced Pharmacology and Neuroscience Laboratory, Department of Pharmacology, School of Health Sciences, Central University of Punjab, Ghudda, Bathinda, 151401, Punjab, India. harikrishnareddy0011@gmail.com.

ORCID-Profile: Dibbanti HariKrishnaReddy

Zitieren

APA

Dhapola, R., Kumari, S., Sharma, P., Paidlewar, M., Vellingiri, B., Cho, S. G., Dayem, A. A., Medhi, B., & HariKrishnaReddy, D. (2026). Stem cells and derived growth factors in Alzheimer’s disease: mechanistic insights and translational perspectives. Inflammopharmacology, 34(11), 7009-7023. https://doi.org/10.1007/s10787-026-02418-9

Vancouver

Dhapola R, Kumari S, Sharma P, Paidlewar M, Vellingiri B, Cho SG, et al. Stem cells and derived growth factors in Alzheimer’s disease: mechanistic insights and translational perspectives. Inflammopharmacology. 2026;34(11):7009-7023. doi:10.1007/s10787-026-02418-9

BibTeX
@article{Dhapola2026,
  author = {Dhapola, Rishika and Kumari, Sneha and Sharma, Prajjwal and Paidlewar, Mohit and Vellingiri, Balachandar and Cho, Ssang-Goo and Dayem, Ahmed Abdal and Medhi, Bikash and HariKrishnaReddy, Dibbanti},
  title = {Stem cells and derived growth factors in Alzheimer’s disease: mechanistic insights and translational perspectives},
  journal = {Inflammopharmacology},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {7009--7023},
  doi = {10.1007/s10787-026-02418-9}
}
Kostenlos starten →